- | Leyden Labs
Intranasal Prophylactics For Flu & Coronavirus With Leyden Labs’ Koenraad Wiedhaup
As Leyden Labs Founder & CEO Koenraad Wiedhaup puts it, we breathe in galaxies of viruses on a daily basis. As those viruses multiply and mutate, our approach to mitigating their risks is largely reactive.
- | TFF Pharmaceuticals
Austin company works to launch COVID-19 antibody treatment in new inhaler form
Dale Christensen, with Austin-based drug developer TFF Pharmaceuticals, says they’ve got an easy solution to getting a monoclonal antibody treatment straight to your doorstep — rather than being hooked up to a machine and IV.
- | Cidara Therapeutics
Emerging Drug-Resistant Fungi Threat Offset by Cidara’s Phase III Antifungal Therapy
The cure for this new threat may rest with Cidara Therapeutics’ new antifungal drug, rezafungin. It currently is completing two Phase III trials. One treats candidemia and invasive candidiasis. On the other, rezafungin is used as a prophylactic for the prevention of fungal infections in a high-risk hematology setting. It shows efficacy against Candida spp., Aspergillus spp., Pneumocystis spp. and dermatophytes, can be administered safely at high doses, and it can clear the body of infection quickly.
- | Renovacor
Physics To Genetics: New Treatments For Hereditary Heart Disease
“Renovacor is in a similar situation to the one MyoKardia was in five years ago,” says Dr. Semigran. “We have knowledge of the mechanism of action of dilated cardiomyopathy, where there’s an inadequate amount of a required protein for the heart muscle to function correctly. And fortunately, I think the field of selective gene therapy for the heart has evolved to the point that we’ve got a pretty good chance of targeting the underlying abnormality of the segment of the cardiomyopathy population with a BAG3-associated condition.”
- | Scynexis
Can Ibrexafungerp Treat Candida Auris?
The therapy was developed by Jersey City, New Jersey-based biotechnology company, Scynexis. The company has also been studying ibrexafungerp in its CARES study in hospitalized patients with C. auris.
- | Anima Biotech
Create Value & Success Will Follow, Anima Biotech CEO Yochi Slonim Says
“When big pharma collaborates with biopharma companies, the main risk isn’t the technology, but the commitment of the partner,” according to serial entrepreneur Yochi Slonim, CEO of Anima Biotech. That isn’t merely his opinion. The question arises in partnering meetings routinely.
- | Palisade Bio
Episode 21-29 Reverse engineering success ???
Moira speaks with psychologist Dr. Ron Friedman about “Decoding Greatness … How the Best in the World Reverse Engineer Success”. Then Dr. Tom Hallam from Palisade Bio in San Diego talks about their efforts to solve a major problem post-surgery – how to get your GI track back on track. And Tech Nation Health Chief Correspondent Dr. Daniel Kraft reviews tests to detect Alzheimer’s early.
- | TFF Pharmaceuticals
EPR Podcast Episode 3 – Inhaled and intranasal drug formulations and delivery – Dr Bill Williams, University of Texas
Bill then discussed some of the current applications of the TFF technology – including enhancing the stability of Takeda Vaccine’s norovirus vaccine. “We laid out the premise that in the liquid form, or even the frozen form, that the antigen was losing activity… but in the paper we showed that through TFF this norovirus vaccine could be stabilised – we are up to several months at 40°C,” he enthused, an amazing achievement since most vaccines require cold chain storage and Pfizer and BioNTech’s mRNA COVID-19 vaccine required ultra-low refrigeration (-70°C or -80°C) to be distributed originally.
